Key result
Steatohepatitis is linked to ~8-fold higher risk of major events vs. liver steatosis in STEMI.
Why the study?
The study was conducted to evaluate the features of STEMI in patients with two types of MAFLD: liver steatosis and steatohepatitis.
Does steatohepatitis worsen clinical and angiographic outcomes in patients with STEMI and MAFLD compared to liver steatosis?
Cohort (n=71)
Yes
Does steatohepatitis worsen clinical and angiographic outcomes in patients with STEMI and MAFLD compared to liver steatosis?
In patients with STEMI and MAFLD, the presence of steatohepatitis is associated with higher thrombus burden, more complex PCI, and significantly worse 18-month cardiovascular outcomes compared to simple liver steatosis.
Highlights steatohepatitis as a prognostic marker in STEMI with MAFLD; hypothesis-generating and requires prospective validation.
To evaluate the features of ST-segment elevation myocardial infarction (STEMI) in patients with two types of metabolic-associated fatty liver disease (MAFLD), that is, liver steatosis (LS) and steatohepatitis (SH).
No takes yet. Share an insight, caveat, or question.
Tretyakova et al. (2023) conducted a cohort in ST-segment elevation myocardial infarction with metabolic-associated fatty liver disease (n=71). Steatohepatitis vs. Liver steatosis was evaluated on Adverse cardiovascular events within 18 months (HR 8.52, 95% CI 5.77-11.04). Steatohepatitis in patients with ST-segment elevation myocardial infarction was associated with an 8.52-fold increased risk of adverse cardiovascular events within 18 months compared to liver steatosis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: